Pure Global AI
NCT06102720Recruiting

Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization

Two-center, Prospective, Randomized, Open-label, Controlled Clinical Trial With Endpoint Evaluation
Mikhail ZykovPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ischemic Stroke
Drug/Device/Intervention
Colchicine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mikhail Zykov
Funder
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Location
Kemerovo,Sochi, Russian Federation
Timeline & enrollment
Phase
Phase 4
Start date
Jan 12, 2023
End date
Feb 01, 2025
Enrollment
200 participants
Primary outcome

Any new stroke events,Neurological deterioration

Summary

This study is two-center, prospective, randomized, open-label, controlled,
 investigator-sponsored study that aims to investigate the efficacy of low-dose colchicine in
 preventing recurrent stroke in the patients with acute atherothrombotic minor-to-moderate
 ischemic stroke during hospitalization.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedOther cerebral infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06102720
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06102720 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mikhail Zykov and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.